Philadelphia positive acute lymphocytic leukaemia – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Thu, 18 Jun 2026 04:07:49 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Philadelphia positive acute lymphocytic leukaemia – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of olverembatinib with chemotherapy versus standard therapy in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia https://clinicaltrials.eu/trial/study-of-olverembatinib-with-chemotherapy-versus-standard-therapy-in-adults-with-newly-diagnosed-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia/ Wed, 29 Apr 2026 15:07:22 +0000 https://clinicaltrials.eu/trial/study-of-olverembatinib-with-chemotherapy-versus-standard-therapy-in-adults-with-newly-diagnosed-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia/ This clinical trial is studying a treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) in newly diagnosed patients. The study tests a new medication called olverembatinib used together with chemotherapy drugs. The chemotherapy medications include vincristine, cytarabine, methotrexate, dexamethasone, and prednisolone.

The study compares two treatment approaches: one group receives olverembatinib with chemotherapy, while the other group receives different medications called tyrosine kinase inhibitors (which may include dasatinib, ponatinib, or imatinib) combined with the same chemotherapy drugs. The main purpose is to find out how well olverembatinib works compared to current treatments in eliminating cancer cells from the body.

During the study, patients will receive their assigned medications for several months. Doctors will regularly check the amount of cancer cells in the blood and bone marrow to see how well the treatment is working. They will also monitor patients for any side effects from the medications and track their overall health and survival over time.

]]> Study on Ponatinib and Blinatumomab for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia https://clinicaltrials.eu/trial/study-on-ponatinib-and-blinatumomab-for-adults-with-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia/ Wed, 29 Apr 2026 14:58:51 +0000 https://clinicaltrials.eu/trial/study-on-ponatinib-and-blinatumomab-for-adults-with-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia/ This clinical trial is focused on studying a type of blood cancer called Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL). The study aims to compare two different treatment approaches for this disease. One approach involves using a combination of two medications, Ponatinib and Blinatumomab, which is a specific type of protein called a monoclonal antibody. The other approach uses traditional chemotherapy combined with another medication called Imatinib. The purpose of the study is to determine which treatment is more effective in improving the condition of patients with Ph+ ALL.

Participants in the study will receive either the combination of Ponatinib and Blinatumomab or the chemotherapy and Imatinib treatment. The study will begin with an induction phase, where Ponatinib is administered along with steroids, followed by Blinatumomab as a consolidation treatment. The alternative treatment involves a chemotherapy regimen combined with Imatinib. The study will monitor the participants over a period to assess the effectiveness of these treatments in terms of event-free survival, which includes factors like the absence of disease markers, survival rates, and any side effects or resistance to the treatment.

The trial will also explore additional aspects such as the ability of Blinatumomab to further reduce disease markers after Ponatinib treatment, the duration of complete remission, and overall survival rates at one and three years. The safety profile of the treatments will be evaluated, focusing on any significant side effects. Additionally, the study will compare the quality of life of patients receiving different treatments over time. This research aims to provide valuable insights into the most effective treatment strategy for adults with Ph+ ALL.

]]> Study Comparing Ponatinib and Imatinib with Chemotherapy for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia https://clinicaltrials.eu/trial/study-comparing-ponatinib-and-imatinib-with-chemotherapy-for-patients-with-newly-diagnosed-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia/ Wed, 29 Apr 2026 14:29:41 +0000 https://clinicaltrials.eu/trial/study-comparing-ponatinib-and-imatinib-with-chemotherapy-for-patients-with-newly-diagnosed-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia/ This clinical trial is focused on studying a type of blood cancer called Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL). The study is comparing two treatments: Ponatinib (AP24534; Iclusig) and Imatinib, both of which are medications taken as film-coated tablets. These treatments are being tested in combination with a type of chemotherapy that is less intense than usual. The purpose of the study is to see how effective these treatments are when used as the first line of therapy for patients who have been newly diagnosed with Ph+ ALL.

Participants in the study will be randomly assigned to receive either Ponatinib or Imatinib, along with the reduced-intensity chemotherapy. The study will observe the participants over a period of time to assess the effectiveness of the treatments. The main goal is to determine how well the treatments work in achieving a state where no cancer cells can be detected in the blood or bone marrow, which is known as a complete remission. The study will also look at other outcomes, such as the duration of remission and overall survival of the participants.

The trial is designed to provide valuable information about the potential benefits and safety of using Ponatinib or Imatinib in treating Ph+ ALL. By comparing these two treatments, researchers hope to find the most effective approach for managing this type of leukemia. Participants will be closely monitored throughout the study to ensure their safety and to gather data on the effectiveness of the treatments.

]]>